Skip to main content

PMV Pharmaceuticals, Inc.

PMVP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001699382

No open-market purchases or sales by PMV Pharmaceuticals, Inc. insiders were filed in the last 90 days; 64 institutions reported holding it in 13F filings for Q2 2026, worth $45.9M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by PMV Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for PMV Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for PMV Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Levine Arnold JDirector409,842Jun 5, 20261
Gallagher Carol GiltnerDirector–Jun 5, 20261
Baum Charles MDirector–Jun 5, 20261
Stelzer LaurieDirector–Jun 5, 20261
Flowers KirstenDirector–Jun 5, 20261
Mack David HenryPresident and CEO451,109Mar 9, 20262
Ticktin RobertGeneral Counsel & COO98,695Mar 9, 20261
Jalota DeepikaChief Development Officer89,959Mar 9, 20261
Carulli MichaelChief Financial Officer60,146Mar 9, 20261
OrbiMed Advisors LLC10% Owner4,975,291IndirectOct 27, 20251
OrbiMed Capital GP V LLC10% Owner4,975,291IndirectOct 27, 20251
Heyman Richard A.Director–Jun 9, 20250
OrbiMed Genesis GP LLC10% Owner0IndirectNov 24, 20230
Alland LeilaChief Medical Officer45,909Sep 18, 20230
Kung WinstonCOO, CFO10,600May 15, 20230
OrbiMed Capital LLC10% Owner0IndirectMar 31, 20220
Schroeder ThiloDirector1,101,283IndirectOct 8, 20210
Nasr Khaled10% Owner25,552IndirectJul 14, 20210
Kliman Gilbert H10% Owner25,552IndirectJul 14, 20210
Interwest Partners X LP10% Owner25,552IndirectJul 14, 20210
InterWest Management Partners X, LLC10% Owner25,552IndirectJul 14, 20210
Desai Keval10% Owner25,552IndirectJul 14, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 8, 2021 (view filing)Jul 71 dayAlland LeilaChief Medical OfficerSSale−4.00K$32.30−$129.2K−100.0%0 after2 lots
Jul 8, 2021 (view filing)Jul 8Same dayKung WinstonCOO, CFOSSale−4.50K$33.75−$151.9K−73.8%1.60K after
Jul 22, 2021 (view filing)Jul 20-212 daysMack David HenryPresident and CEOSSale−27.8K$35.75−$993.7K−69.0%12.5K after2 lots
Jul 22, 2021 (view filing)Jul 202 daysLevine Arnold JDirectorSSale−3.50K$35.12−$122.9K−0.8%416.8K after
Jul 23, 2021 (view filing)Jul 21-222 daysSchroeder ThiloDirectorSSale−18.9K$35.82−$676.0K−0.9%2.02M after2 lots
Jul 27, 2021 (view filing)Jul 23-274 daysSchroeder ThiloDirectorSSale−17.4K$35.91−$623.5K−0.9%2.00M after3 lots
Jul 30, 2021 (view filing)Jul 28-292 daysSchroeder ThiloDirectorSSale−11.0K$35.75−$394.1K−0.6%1.99M after2 lots
Aug 4, 2021 (view filing)Aug 31 dayKung WinstonCOO, CFOSSale−4.50K$33.82−$152.2K−73.8%1.60K after
Aug 4, 2021 (view filing)Aug 2-42 daysSchroeder ThiloDirectorSSale−96.1K$35.05−$3.37M−4.8%1.90M after7 lots
Aug 9, 2021 (view filing)Aug 5-94 daysSchroeder ThiloDirectorSSale−77.7K$36.23−$2.81M−4.1%1.82M after7 lots
Aug 10, 2021 (view filing)Aug 91 dayAlland LeilaChief Medical OfficerSSale−4.47K$34.04−$152.2K−100.0%0 after3 lots
Aug 12, 2021 (view filing)Aug 10-122 daysSchroeder ThiloDirectorSSale−68.5K$34.36−$2.35M−3.8%1.75M after5 lots
Aug 17, 2021 (view filing)Aug 13-174 daysSchroeder ThiloDirectorSSale−80.5K$33.89−$2.73M−4.6%1.67M after6 lots
Aug 18, 2021 (view filing)Aug 171 dayJalota DeepikaSVP, Regulatory Affairs and QASSale−2.90K$33.78−$97.8K−100.0%0 after
Aug 20, 2021 (view filing)Aug 18-192 daysSchroeder ThiloDirectorSSale−30.7K$33.05−$1.01M−1.8%1.64M after4 lots
Aug 24, 2021 (view filing)Aug 231 dayLevine Arnold JDirectorSSale−3.50K$29.50−$103.3K−0.8%413.3K after
Aug 25, 2021 (view filing)Aug 23-252 daysSchroeder ThiloDirectorSSale−51.9K$30.87−$1.60M−3.2%1.59M after4 lots
Aug 30, 2021 (view filing)Aug 26-304 daysSchroeder ThiloDirectorSSale−58.8K$30.45−$1.79M−4.5%1.24M after5 lots
Sep 2, 2021 (view filing)Aug 31-Sep 22 daysSchroeder ThiloDirectorSSale−46.9K$30.25−$1.42M−3.8%1.20M after3 lots
Sep 8, 2021 (view filing)Sep 71 dayAlland LeilaChief Medical OfficerSSale−3.90K$30.25−$118.0K−100.0%0 after
Sep 10, 2021 (view filing)Sep 91 dayAlland LeilaChief Medical OfficerSSale−100$30.25−$3.02K−100.0%0 after
Sep 13, 2021 (view filing)Sep 9-134 daysSchroeder ThiloDirectorSSale−70.8K$30.41−$2.15M−5.9%1.12M after4 lots
Sep 21, 2021 (view filing)Sep 174 daysSchroeder ThiloDirectorSSale−711$30.03−$21.4K−0.1%1.12M after
Sep 23, 2021 (view filing)Sep 221 dayLevine Arnold JDirectorSSale−3.50K$30.00−$105.0K−0.8%409.8K after
Sep 24, 2021 (view filing)Sep 222 daysSchroeder ThiloDirectorSSale−100$30.00−$3.00K0.0%1.12M after
Sep 29, 2021 (view filing)Sep 27-292 daysSchroeder ThiloDirectorSSale−7.46K$30.06−$224.3K−0.7%1.12M after2 lots
Oct 4, 2021 (view filing)Sep 30-Oct 44 daysSchroeder ThiloDirectorSSale−14.6K$30.09−$439.8K−1.3%1.10M after3 lots
Oct 8, 2021 (view filing)Oct 62 daysSchroeder ThiloDirectorSSale−800$30.15−$24.1K−0.1%1.10M after
Mar 31, 2022 (view filing)5:30 PM ETMar 29-312 daysOrbiMed Advisors LLC and 3 others10% OwnerSSale−474.5K$21.63−$10.3M−100.0%0 after3 lots
May 31, 2022 (view filing)4:36 PM ETMay 265 daysOrbiMed Advisors LLC and 2 others10% OwnerSSale−26.3K$15.93−$418.2K−23.0%87.8K after
Sep 18, 2023 (view filing)Sep 153 daysAlland LeilaChief Medical OfficerSSale−6.29K$6.62−$41.6K−12.1%45.9K after
Sep 18, 2023 (view filing)Sep 153 daysJalota DeepikaChief Development OfficerSSale−4.10K$6.62−$27.2K−12.1%29.9K after
Nov 24, 2023 (view filing)4:38 PM ETNov 222 daysOrbiMed Advisors LLC and 2 others10% OwnerSSale−87.8K$2.23−$195.8K−100.0%0 after
Sep 12, 2024 (view filing)Sep 111 dayCarulli MichaelChief Financial OfficerSSale−2.89K$1.50−$4.34K−3.2%88.4K after
Sep 12, 2024 (view filing)Sep 111 dayJalota DeepikaChief Development OfficerSSale−7.22K$1.50−$10.8K−5.8%118.3K after
Jul 3, 2025 (view filing)Jul 12 daysMack David HenryPresident and CEOSSale−58.4K$1.06−$61.9K−9.8%536.1K after
Jul 3, 2025 (view filing)Jul 12 daysCarulli MichaelChief Financial OfficerSSale−28.2K$1.06−$29.9K−32.0%60.1K after
Jul 3, 2025 (view filing)Jul 12 daysJalota DeepikaChief Development OfficerSSale−33.1K$1.06−$35.0K−26.9%90.0K after
Jul 3, 2025 (view filing)Jul 12 daysTicktin RobertGeneral Counsel & COOSSale−23.2K$1.06−$24.5K−19.0%98.7K after
Sep 12, 2025 (view filing)5:09 PM ETSep 102 daysOrbiMed Advisors LLC and 1 other10% OwnerSSale−500.0K$1.80−$900.0K−7.7%5.98M after
Oct 27, 2025 (view filing)5:19 PM ETOct 234 daysOrbiMed Advisors LLC and 1 other10% OwnerSSale−1.00M$1.52−$1.52M−16.7%4.98M after